North America Long Read Sequencing Market Analysis 2025–2035
The North America Long Read Sequencing Market is experiencing robust growth, driven by breakthroughs in genomics and expanding applications in clinical diagnostics and research. Technologies like SMRT and nanopore sequencing are increasingly adopted for their ability to deliver comprehensive genomic insights, supporting precision medicine, cancer genomics, and rare disease identification. A dynamic landscape marked by rapid product innovation and strategic collaborations among leading players underpins market expansion, while the sector continues to overcome technical and regulatory challenges.
Understanding the Impact of Tariffs on "North America Long Read Sequencing Market".
Latest Market Dynamics
Key Drivers
- Technological advancements in long read sequencing, including improved accuracy of SMRT and nanopore systems, are accelerating adoption rates. For example, PacBio introduced enhanced chemistries in 2024, boosting throughput and cost efficiency.
- Rising demand for precision medicine is fueling growth. In June 2024, Oxford Nanopore Technologies announced partnerships with leading research hospitals to deliver real-time, in-clinic sequencing, supporting tailored cancer and genetic disorder therapies.
Key Trends
- Integration of AI with long read sequencing for automated variant detection is gaining traction. Illumina, in alliance with multiple research institutions, launched an AI-driven platform in July 2024, optimizing data interpretation speed and accuracy.
- Increasing deployment of cloud-based genomic analysis solutions is notable. BGI Genomics expanded its cloud services in August 2024, facilitating seamless long read data sharing and analytics for researchers across North America.
Key Opportunities
- Adoption in clinical and diagnostic settings remains a key opportunity. Roche collaborated with major hospital networks in September 2024 to implement long read sequencing for routine diagnostic workflows, targeting oncology and hereditary disease panels.
- Expanding research funding for human genomic projects presents additional market opportunities. The NIH’s Freshwater Genomics Initiative, launched in October 2024, leverages long read sequencing to understand genetic susceptibility to environmental factors.
Key Challenges
- High operational and instrument costs persist as barriers. Quantapore’s recent attempt to scale mid-cost platforms highlights ongoing struggles to balance affordability and technology sophistication.
- Complex data analysis and storage requirements challenge scalability. Genapsys, for example, invested in new bioinformatics tools in November 2024 to simplify large-scale long read sequencing dataset management.
Key Restraints
- Stringent regulatory requirements for clinical implementation delay product launches. Agilent Technologies faced extended review timelines for its new long read system in late 2024.
- Limited skilled workforce for advanced genomics hampers adoption rates, with companies like Nabsys investing heavily in workforce training programs to bridge knowledge gaps.
North America Long Read Sequencing Market Share by Type, 2025
The long read sequencing market in North America showcases a dominant share for Single-Molecule Real-Time (SMRT) Sequencing, owing to its matured applications across research, clinical, and diagnostics. Nanopore sequencing closely follows, gaining traction for field deployment and portable workflows. The presence of synthetic and hybrid sequencing technologies reflects the market’s inclination towards comprehensive genome coverage and improved accuracy. As innovation continues, the market mix is expected to gradually shift with the advancement of more accessible and cost-effective solutions.
North America Long Read Sequencing Market Share by Application, 2025
De Novo sequencing accounts for the highest proportion of applications in the North America market, as it remains vital for assembling new genomes without reference data. Cancer genomics is witnessing rapid growth, reflecting the demand for precision oncology solutions and actionable insights from complex cancer genomes. Variant detection continues to be crucial, especially in hereditary disease research and clinical diagnostics, ensuring comprehensive genomic understanding.
North America Long Read Sequencing Market Revenue (USD Million), 2020-2035
The North America Long Read Sequencing Market has demonstrated significant revenue growth from 2020 through 2025, with an upswing from 485 Million USD in 2020 to an estimated 1,192 Million USD in 2025. Projected forecasts highlight further acceleration, reaching approximately 4,980 Million USD by 2035. Growth is attributed to technological innovations, broadening clinical applications, and increased research funding. The upward trajectory reflects expanding adoption beyond academic research into mainstream diagnostics and personalized healthcare.
North America Long Read Sequencing Market YOY Growth (%), 2020-2035
Year-over-year growth rates in the North America Long Read Sequencing Market have been robust, peaking during initial adoption phases and stabilizing as the technologies mature. From 2020 to 2025, YOY growth averaged approximately 19%, propelled by early technological advances and increased funding. From 2025 through 2035, the market still records healthy double-digit growth, averaging 15%, supported by clinical integration and affordable platform launches. This consistent expansion underscores sustained demand and rapid market evolution.
North America Long Read Sequencing Market Share by Region, 2025
The United States maintains the largest share of the North America Long Read Sequencing Market, owing to its strong biotechnology ecosystem, active research landscape, and major vendor presence. Canada follows, supported by expanding genomic medicine programs and government investments. Mexico's share is rising as healthcare and academic institutions adopt next-generation sequencing solutions, albeit at a slower pace compared to its northern counterparts.
North America Long Read Sequencing Market Share by Players, 2025
PacBio and Oxford Nanopore Technologies lead the North America Long Read Sequencing Market, collectively holding the majority share. Their continued innovation and comprehensive platform offerings solidify their dominance. Illumina, while strong in short read sequencing, is growing its presence in long read applications through partnerships. Regional and emerging firms, such as BGI Genomics, round out the market landscape with tailored solutions.
North America Long Read Sequencing Market Share by Buyers, 2025
Research institutes stand as the largest buyers of long read sequencing platforms in 2025, aligning with their focus on population genomics and discovery science. Hospitals and clinical labs are increasing adoption for diagnostic and oncology applications. Pharmaceutical and biotechnology companies represent a substantial share, leveraging long read technologies for drug development and biomarker discovery.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 1192 |
| Regions | United States, Canada, Mexico |
| Segments | By Type (SMRT Sequencing, Nanopore Sequencing, Synthetic Long-Read Sequencing, Linked-Read Sequencing, Hybrid Sequencing, Others); By Application (De Novo Sequencing, Variant Detection, Transcriptome Analysis, Epigenetics, Cancer Genomics, Others); By Technology (SMRT Sequencing, Nanopore Sequencing, Linked-Read Sequencing, Synthetic Long-Read Sequencing, Hybrid Sequencing, Others); By Distribution Channels (Direct Sales, Distributors, Online Sales, Research Institutes, Hospitals, Others); By Organization Size (Small, Medium, Large) |
| Players | PacBio, Oxford Nanopore Technologies, Illumina, BGI Genomics, Quantapore, Stratos Genomics, QIAGEN, Genapsys, Roche, Nabsys, Dovetail Genomics, Longas Technologies, Agilent Technologies, ZS Genetics, Other Key Players |
Key Recent Developments
- June 2024: PacBio announced the release of its Revio system with upgraded chemistries, increasing yields in human whole genome sequencing.
- July 2024: Oxford Nanopore Technologies entered a strategic partnership with a US cancer center to deploy rapid sequencing for real-time oncology diagnostics.
- August 2024: BGI Genomics expanded its North America presence by unveiling cloud-enabled genomic analytics specifically optimized for long read sequencing data.
- September 2024: Roche collaborated with several major hospital networks to introduce long read sequencing workflows in hereditary cancer screening.
- November 2024: Genapsys launched a simplified data analysis toolkit to accelerate interpretation of large-scale long read sequencing datasets for academic and clinical use.
